SSG
CCCC icon

Summit Securities Group’s C4 Therapeutics CCCC Stock Holding History

Summit Securities Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.87K Buy
+829
New +$2.83K ﹤0.01% 1022
2025
Q3 		– Sell
-2,122
Closed -$3.03K – 1065
2025
Q2 		$3.03K Buy
2,122
+1,967
+1,269% +$2.86K ﹤0.01% 1008
2025
Q1 		$248 Buy
+155
New +$462 ﹤0.01% 732
2024
Q4 		– Sell
-143
Closed -$1K – 672
2024
Q3 		$1K Buy
+143
New +$861 ﹤0.01% 506

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Summit Securities Group's CCCC Position: Q2 2026 in Review

Summit Securities Group opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 829 shares worth $3.87K. The stake represents ﹤0.01% of the portfolio and ranks #1022 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in CCCC as recently as Q2 2025.

Summit Securities Group first reported a position in CCCC in Q3 2024 and has held it in 4 quarters since. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Summit Securities Group held 829 shares of C4 Therapeutics worth $3.87K as of Q2 2026.
  • C4 Therapeutics was a new Summit Securities Group position in Q2 2026.
  • C4 Therapeutics made up ﹤0.01% of Summit Securities Group's portfolio in Q2 2026, its #1022 holding.
  • Summit Securities Group first reported a position in C4 Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.